Astrocytoma is the most common malignant brain tumor in humans and is currently incurable due to its diffusely infiltrative behavior. We have developed a mouse model of astrocytoma that recapitulates the infiltrative behavior of human astrocytoma. In this mouse model the tumor suppressor genes Nf1 and p53 are mutated. Because both NF1 and p53 are frequently mutated in sporadic glioblastoma (GBM), this mouse model is a powerful tool for understanding the biology of tumors associated with neurofibromatosis type 1, as well as sporadic anaplastic astrocytomas and glioblastomas. We are using this mouse model to examine the signal transduction pathways necessary for proliferation and migration of astrocytoma cells both in vivo and in vitro. An understanding of these mechanisms will lead to the development of new therapies for astrocytoma.During fiscal year 2012, we focused on the role of the transcription factor, Cdca7l, on cell proliferation and cell death. This gene is a candidate for the Arlm1 modifier we identified in Project 1, and has been shown by others to interact with the oncogene myc. It also plays a normal role in the brain regulating MAO and downstream catecholamine pathways. Because these catecholamine pathways have been extensively targeted for psychotherapy, we are examining the potential role of these pathways in driving or inhibiting brain cancer.In addition to these cell-based studies, we have been extending our in vitro studies on PDGFR to in vivo studies. We are currently examining how loss of PDGFR in the astrocyte lineage affects the development of astrocytoma and glioblastoma in our Nf1/p53 mouse model. We are aging mice for this study and examining their brain tumor phenotype for whether they develop fewer tumors or whether the tumors develop with overexpression of a different receptor tyrosine kinase, such as EGFR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010540-10
Application #
8552728
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2012
Total Cost
$240,123
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Zemp, Franz J; McKenzie, Brienne A; Lun, Xueqing et al. (2013) Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon. PLoS One 8:e65801
Amlin-Van Schaick, Jessica C; Kim, Sungjin; DiFabio, Christina et al. (2012) Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. Neuro Oncol 14:160-74
Gursel, Demirkan B; Connell-Albert, Yvette S; Tuskan, Robert G et al. (2011) Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro Oncol 13:610-21
Walrath, Jessica C; Hawes, Jessica J; Van Dyke, Terry et al. (2010) Genetically engineered mouse models in cancer research. Adv Cancer Res 106:113-64
Banerjee, Sutapa; Byrd, Jonathan N; Gianino, Scott M et al. (2010) The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 70:1356-66
Reilly, Karlyne M (2009) Neurofibromatosis and lessons for the war on cancer. EMBO Mol Med 1:198-200
Reilly, Karlyne M; Rubin, Joshua B; Gilbertson, Richard J et al. (2008) Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. Cancer Res 68:5508-11
Reilly, Karlyne M; Van Dyke, Terry (2008) It takes a (dysfunctional) village to raise a tumor. Cell 135:408-10